Expertise in
23
conditions

Dr. William R. Lumry

Internal Medicine
William R. Lumry M.D. P.A.
10100 N Central Expy Ste 100, 
Dallas, TX 
Expertise in
23
conditions
William R. Lumry M.D. P.A.
10100 N Central Expy Ste 100, 
Dallas, TX 

Overview

William Lumry is a primary care provider, practicing in Internal Medicine in Dallas, Texas.

Dr. Lumry is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Hereditary Angioedema, Angioedema, Hives, and Primary Immunodeficiency (PID).

He is actively involved in clinical research, co-authoring 136 peer reviewed articles and participating in 7 clinical trials.

Specialties

Internal Medicine

Licenses

Specialist in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

William R. Lumry M.D. P.A.
10100 N Central Expy Ste 100, Dallas, TX 75231

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naïve Subjects With Primary Immunodeficiency
A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naïve Subjects With Primary Immunodeficiency
Enrollment Status: Completed
Publish Date: September 29, 2023
Intervention Type: Biological
Study Phase: Phase 4
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: No_longer_available
Publish Date: July 24, 2023
Intervention Type: Drug
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: CDX-0159, Normal Saline
Study Phase: Phase 1
A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral Immunodeficiency
A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral Immunodeficiency
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Biological
Study Phase: Phase 3
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
Enrollment Status: Completed
Publish Date: March 30, 2023
An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
Enrollment Status: Completed
Publish Date: December 09, 2022
Intervention Type: Biological
Study Phase: Phase 3
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
Enrollment Status: Completed
Publish Date: May 26, 2022
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
View 6 Less Clinical Trials

136 Total Publications

Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema.
Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema.
Journal: The New England journal of medicine
Published: June 15, 2026
Similar Doctors
Expertise in
223
conditions
Dr. Yu W. Chen
Internal Medicine
Expertise in
223
conditions
Dr. Yu W. Chen
Internal Medicine
Before you request

UT Southwestern - Internal Medicine

5939 Harry Hines Blvd, 8th Fl Ste 124, 
Dallas, TX 
 (6.8 miles away)
214-645-3597
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Yu Chen is a primary care provider, practicing in Internal Medicine in Dallas, Texas. Dr. Chen is highly rated in 223 conditions, according to our data. Her clinical expertise encompasses Cerebral Hypoxia, Acute Tubular Necrosis, IgG4-Related Disease, Endovascular Embolization, and Endoscopy. Dr. Chen is currently accepting new patients.

Expertise in
30
conditions
Dr. Arturo R. Dominguez
Internal Medicine
Expertise in
30
conditions
Dr. Arturo R. Dominguez
Internal Medicine
Before you request

Dallas County Hospital District

5200 Harry Hines Blvd, 
Dallas, TX 
 (6.6 miles away)
214-590-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arturo Dominguez is a primary care provider, practicing in Internal Medicine in Dallas, Texas. Dr. Dominguez is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Cicatricial Pemphigoid, Bullous Pemphigoid, Erythema Multiforme, Stevens-Johnson Syndrome, and Angioplasty. Dr. Dominguez is currently accepting new patients.

Expertise in
20
conditions
Dr. James B. Galloway
Internal Medicine
Expertise in
20
conditions
Dr. James B. Galloway
Internal Medicine
Before you request

UT Southwestern - Internal Medicine

5939 Harry Hines Blvd, 8th Fl Ste 124, 
Dallas, TX 
 (6.8 miles away)
214-645-3597
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Galloway is a primary care provider, practicing in Internal Medicine in Dallas, Texas. Dr. Galloway is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Arthritis, Necrosis, COVID-19, Severe Acute Respiratory Syndrome (SARS), and Hormone Replacement Therapy (HRT). Dr. Galloway is currently accepting new patients.

Frequently Asked Questions about Dr. William R. Lumry

How do I make an appointment with Dr. William R. Lumry?

You can book an appointment with Dr. William R. Lumry by calling their office at 214-373-7374. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. William R. Lumry a top-rated expert for Hereditary Angioedema?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. William R. Lumry is classified as an Elite expert for Hereditary Angioedema, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. William R. Lumry specialize in?

While Dr. William R. Lumry is a Internal Medicine, they have specific expertise in Hereditary Angioedema, Angioedema, and Hives. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. William R. Lumry participate in research or clinical trials?

Yes. Dr. William R. Lumry has published 136 articles and abstracts on conditions like Hereditary Angioedema. You can view a list of Dr. William R. Lumry's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. William R. Lumry accept my insurance?

Dr. William R. Lumry accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 214-373-7374 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lumry's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile